These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Druggability of CRMP2 for Neurodegenerative Diseases. Khanna R; Moutal A; Perez-Miller S; Chefdeville A; Boinon L; Patek M ACS Chem Neurosci; 2020 Sep; 11(17):2492-2505. PubMed ID: 32693579 [TBL] [Abstract][Full Text] [Related]
4. Non-SUMOylated CRMP2 decreases Na Gomez K; Ran D; Madura CL; Moutal A; Khanna R Mol Brain; 2021 Jan; 14(1):20. PubMed ID: 33478555 [TBL] [Abstract][Full Text] [Related]
5. Edonerpic maleate regulates glutamate receptors through CRMP2- and Arc-mediated mechanisms in response to brain trauma. Chen T; Yang LK; Ai P; Zhu J; Hang CH; Wang YH Cell Death Discov; 2022 Mar; 8(1):95. PubMed ID: 35246523 [TBL] [Abstract][Full Text] [Related]
6. Differential expression of Cdk5-phosphorylated CRMP2 following a spared nerve injury. Moutal A; Ji Y; Bellampalli SS; Khanna R Mol Brain; 2020 Jun; 13(1):97. PubMed ID: 32571373 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of CRMP2 phosphorylation repairs CNS by regulating neurotrophic and inhibitory responses. Nagai J; Owada K; Kitamura Y; Goshima Y; Ohshima T Exp Neurol; 2016 Mar; 277():283-295. PubMed ID: 26795088 [TBL] [Abstract][Full Text] [Related]
10. Dissecting the role of the CRMP2-neurofibromin complex on pain behaviors. Moutal A; Wang Y; Yang X; Ji Y; Luo S; Dorame A; Bellampalli SS; Chew LA; Cai S; Dustrude ET; Keener JE; Marty MT; Vanderah TW; Khanna R Pain; 2017 Nov; 158(11):2203-2221. PubMed ID: 28767512 [TBL] [Abstract][Full Text] [Related]
11. Activity of T-type calcium channels is independent of CRMP2 in sensory neurons. Cai S; Shan Z; Zhang Z; Moutal A; Khanna R Channels (Austin); 2019 Dec; 13(1):147-152. PubMed ID: 31025580 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of the Ubc9 E2 SUMO-conjugating enzyme-CRMP2 interaction decreases NaV1.7 currents and reverses experimental neuropathic pain. François-Moutal L; Dustrude ET; Wang Y; Brustovetsky T; Dorame A; Ju W; Moutal A; Perez-Miller S; Brustovetsky N; Gokhale V; Khanna M; Khanna R Pain; 2018 Oct; 159(10):2115-2127. PubMed ID: 29847471 [TBL] [Abstract][Full Text] [Related]
13. CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide. Moutal A; Yang X; Li W; Gilbraith KB; Luo S; Cai S; François-Moutal L; Chew LA; Yeon SK; Bellampalli SS; Qu C; Xie JY; Ibrahim MM; Khanna M; Park KD; Porreca F; Khanna R Pain; 2017 Dec; 158(12):2301-2319. PubMed ID: 28809766 [TBL] [Abstract][Full Text] [Related]
14. Sustained relief of ongoing experimental neuropathic pain by a CRMP2 peptide aptamer with low abuse potential. Xie JY; Chew LA; Yang X; Wang Y; Qu C; Wang Y; Federici LM; Fitz SD; Ripsch MS; Due MR; Moutal A; Khanna M; White FA; Vanderah TW; Johnson PL; Porreca F; Khanna R Pain; 2016 Sep; 157(9):2124-2140. PubMed ID: 27537210 [TBL] [Abstract][Full Text] [Related]
15. The Natural Flavonoid Naringenin Elicits Analgesia through Inhibition of NaV1.8 Voltage-Gated Sodium Channels. Zhou Y; Cai S; Moutal A; Yu J; Gómez K; Madura CL; Shan Z; Pham NYN; Serafini MJ; Dorame A; Scott DD; François-Moutal L; Perez-Miller S; Patek M; Khanna M; Khanna R ACS Chem Neurosci; 2019 Dec; 10(12):4834-4846. PubMed ID: 31697467 [TBL] [Abstract][Full Text] [Related]
16. CRMP2-derived peptide ST2-104 (R9-CBD3) protects SH-SY5Y neuroblastoma cells against Aβ Ji Y; Hu Y; Ren J; Khanna R; Yao Y; Chen Y; Li Q; Sun L Chem Biol Interact; 2019 May; 305():28-39. PubMed ID: 30871964 [TBL] [Abstract][Full Text] [Related]
17. A membrane-delimited N-myristoylated CRMP2 peptide aptamer inhibits CaV2.2 trafficking and reverses inflammatory and postoperative pain behaviors. François-Moutal L; Wang Y; Moutal A; Cottier KE; Melemedjian OK; Yang X; Wang Y; Ju W; Largent-Milnes TM; Khanna M; Vanderah TW; Khanna R Pain; 2015 Jul; 156(7):1247-1264. PubMed ID: 25782368 [TBL] [Abstract][Full Text] [Related]
18. Homology-guided mutational analysis reveals the functional requirements for antinociceptive specificity of collapsin response mediator protein 2-derived peptides. Moutal A; Li W; Wang Y; Ju W; Luo S; Cai S; François-Moutal L; Perez-Miller S; Hu J; Dustrude ET; Vanderah TW; Gokhale V; Khanna M; Khanna R Br J Pharmacol; 2018 Jun; 175(12):2244-2260. PubMed ID: 28161890 [TBL] [Abstract][Full Text] [Related]
19. Cdk5-mediated CRMP2 phosphorylation is necessary and sufficient for peripheral neuropathic pain. Moutal A; Luo S; Largent-Milnes TM; Vanderah TW; Khanna R Neurobiol Pain; 2019; 5():. PubMed ID: 31080913 [TBL] [Abstract][Full Text] [Related]
20. Intranasal CRMP2-Ubc9 inhibitor regulates Na V 1.7 to alleviate trigeminal neuropathic pain. Loya-Lopez SI; Allen HN; Duran P; Calderon-Rivera A; Gomez K; Kumar U; Shields R; Zeng R; Dwivedi A; Saurabh S; Korczeniewska OA; Khanna R Pain; 2024 Mar; 165(3):573-588. PubMed ID: 37751532 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]